Applied Sciences
| Open Access |
DOI: Conventional vs. Emerging Therapeutic Approaches in Parkinson’s Disease: Challenges and Prospects
Aymma Athar , Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow – 226028, India Mohd Jari Hasan Rizvi , Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow – 226028, India Aditi Singh , Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow – 226028, IndiaAbstract
Parkinson's disease is a progressive neurodegenerative disorder that causes motor symptoms such as tremor, stiffness, bradykinesia, and postural instability, as well as a variety of non-motor consequences. Despite being the second most common neurodegenerative illness worldwide, effective disease-modifying medicines are still elusive. For decades, conventional therapy techniques such as levodopa, dopamine agonists, monoamine oxidase-B inhibitors, and deep brain stimulation (DBS) have served as the cornerstone of Parkinson's disease management. While these treatments relieve symptoms and enhance quality of life, their long-term efficacy is restricted by consequences like motor fluctuations, dyskinesias, and decreased responsiveness.
Recent advances in neuroscience have fueled the development of emerging therapies that aim to go beyond symptomatic relief. These include gene therapies targeting dopamine synthesis and α-synuclein aggregation, stem cell–based neuronal replacement strategies, novel neuroprotective agents, and precision medicine approaches. In addition, innovative drug delivery systems and non-invasive neuromodulation techniques are being explored to enhance treatment outcomes.
This review highlights the strengths and limitations of conventional therapies while critically evaluating the promise of emerging approaches. By comparing established practices with novel strategies, the paper underscores the evolving landscape of Parkinson’s disease management and the potential for future interventions to achieve true disease modification.
Keywords
Parkinson’s Disease, dyskinesia, Levodopa, Deep Brain Stimulation, Neurodegenerative
References
Aymma Athar
Download and View Statistics
Copyright License
Copyright (c) 2026 Aymma Athar, Mohd Jari Hasan Rizvi , Aditi Singh
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.